Cardiol Therapeutics Inc. (TSX:CRDL)

Canada · Delayed Price · Currency is CAD

1.730

-0.140 (-7.49%)

Feb 21, 2025, 4:00 PM EST

Cardiol Therapeutics Employees

Cardiol Therapeutics had 6 employees as of December 31, 2018.

Employees

6

Change

n/a

Growth

n/a

Revenue / Employee

n/a

Profits / Employee

n/a

Market Cap

141.17M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2018	6	-	-

Related Stocks

Company Name	Employees
Green Thumb Industries	4,561
dentalcorp Holdings	9,900
WELL Health Technologies	1,507
Curaleaf Holdings	5,650
Sienna Senior Living	12,263
Trulieve Cannabis	5,400
Cronos Group	356
Extendicare	23,000

Employee Rankings

Cardiol Therapeutics News

2 days ago - Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure - Newsfile Corp
4 days ago - Cardiol Therapeutics: Bargain Stock Price With Share Price Appreciation Catalysts - Seeking Alpha
18 days ago - Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Newsfile Corp
2 months ago - PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis - GlobeNewsWire
3 months ago - CBD-Based Drug Reduces Pericarditis Pain And Inflammation, Shows New Clinical Study - Benzinga
3 months ago - Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024 - Newsfile Corp
3 months ago - Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index - GlobeNewsWire
4 months ago - IRW-News: Cardiol Therapeutics Inc. : Cardiol Therapeutics will CardiolRx in eine Studie der späten Phase an Patienten mit rezidivierender Perikarditis überführen - Onvista